Description:

1. Active Substance: Imatinib
   • Glivec/Gleevec contains the active ingredient imatinib mesylate. Imatinib is a targeted therapy drug that falls into the category of tyrosine kinase inhibitors. It is used in the treatment of certain types of cancer.
2. Medical Uses:
   • Chronic Myeloid Leukemia (CML): Imatinib is widely prescribed for the treatment of chronic myeloid leukemia, a type of blood cancer characterized by the abnormal growth of myeloid cells.
   • Gastrointestinal Stromal Tumors (GIST): It is also used to treat gastrointestinal stromal tumors, which are a type of soft tissue sarcoma.
3. Mode of Action:
   • Imatinib works by inhibiting specific tyrosine kinases, which are enzymes involved in the abnormal growth of cancer cells. In CML, it targets the BCR-ABL fusion protein, while in GIST, it inhibits the activity of the c-KIT protein.
4. Dosage and Administration:
   • The dosage of Glivec/Gleevec is determined by a healthcare professional based on the type of cancer being treated, the patient’s overall health, and other factors. It is typically taken orally in the form of tablets.
5. Strengths:
   • Glivec/Gleevec is available in different strengths, and the prescribed dosage will depend on the specific medical condition. Common strengths include 100 mg and 400 mg tablets.
6. Side Effects:
   • Common side effects of imatinib may include nausea, vomiting, diarrhea, muscle cramps, and fatigue. It’s important to report any severe or persistent side effects to the healthcare provider.
7. Precautions:
   • Before using Glivec/Gleevec, individuals should inform their healthcare provider about their medical history, existing medical conditions, and medications they are currently taking. Regular monitoring of blood counts and liver function may be necessary during treatment.
8. Prescription Required:
   • Yes, Glivec/Gleevec is a prescription medication. It should only be used under the supervision of a qualified oncologist or healthcare professional.
9. Duration of Treatment:
   • The duration of treatment with imatinib is often long-term and is determined by the healthcare provider based on the response to treatment and the specific cancer being treated.
10. Note:

• Imatinib has been a groundbreaking drug in the treatment of certain cancers, significantly improving outcomes for many patients. However, its use requires careful monitoring, and patients should communicate openly with their healthcare team about their experiences and any concerns during treatment.

It’s important to note that specific product information and medical guidance may vary, and the information provided here is a general description. Patients should refer to the product information leaflet provided with the medication and consult their healthcare provider for personalized advice.